On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Authors
Keywords
Lung cancer, Oncogene, G12C, Immunotherapy, Targeted therapy
Journal
LUNG CANCER
Volume 160, Issue -, Pages 152-165
Publisher
Elsevier BV
Online
2021-07-16
DOI
10.1016/j.lungcan.2021.07.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
- (2021) Keith M. Kerr et al. LUNG CANCER
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- (2021) Ferdinandos Skoulidis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Resistance to KRASG12C Inhibition in Cancer
- (2021) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
- (2020) Misako Nagasaka et al. CANCER TREATMENT REVIEWS
- A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial
- (2020) S.I. Ou et al. Journal of Thoracic Oncology
- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
- (2020) Todd M. Bauer et al. Targeted Oncology
- Targeting the MAPK Pathway in KRAS-Driven Tumors
- (2020) Matthias Drosten et al. CANCER CELL
- KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
- (2020) Alex Friedlaender et al. CANCER TREATMENT REVIEWS
- Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS–mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan).
- (2020) Yutaro Tamiya et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).
- (2020) Stephen V. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.
- (2020) Kathryn Cecilia Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- The prevalence of KRASG12C mutations utilizing circulating tumor DNA (ctDNA) in 80,911 patients with cancer.
- (2020) Kyaw Thein et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.
- (2020) Maliha Nusrat et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting KRAS G12C ‐mutant cancer with a mutation‐specific inhibitor
- (2020) James G. Christensen et al. JOURNAL OF INTERNAL MEDICINE
- Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
- (2020) Jay B. Fell et al. JOURNAL OF MEDICINAL CHEMISTRY
- The National Lung Matrix Trial of personalized therapy in lung cancer
- (2020) Gary Middleton et al. NATURE
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations
- (2020) Tatu Pantsar Scientific Reports
- KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting
- (2020) Mariantonia Nacchio et al. Journal of Thoracic Disease
- 1339P Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB)
- (2020) S. Aggarwal et al. ANNALS OF ONCOLOGY
- 1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
- (2020) D.S. Hong et al. ANNALS OF ONCOLOGY
- 1279P Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)
- (2020) J. Mazieres et al. ANNALS OF ONCOLOGY
- 1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
- (2020) M. Reck et al. ANNALS OF ONCOLOGY
- Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer
- (2020) H. Adderley et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
- (2020) P.A. Jänne et al. EUROPEAN JOURNAL OF CANCER
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications
- (2020) Hiu Ting Chan et al. Cancers
- A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
- (2020) Jonathan W. Goldman et al. Frontiers in Oncology
- Targeting the untargetable KRAS in cancer therapy
- (2019) Pingyu Liu et al. Acta Pharmaceutica Sinica B
- Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
- (2019) Badi El Osta et al. Journal of Thoracic Oncology
- Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib
- (2019) A J Schoenfeld et al. ANNALS OF ONCOLOGY
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Detection of NRG1 Gene Fusions in Solid Tumors
- (2019) Sushma Jonna et al. CLINICAL CANCER RESEARCH
- Chemotherapy in KRAS-mutated chemotherapy naive non-small cell lung cancer patients: A phase III comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22 (NCT02743923).
- (2019) Anne-Marie C. Dingemans et al. JOURNAL OF CLINICAL ONCOLOGY
- K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
- (2019) Matthias Scheffler et al. Journal of Thoracic Oncology
- Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
- (2019) Miriam Molina-Arcas et al. Science Translational Medicine
- KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer
- (2019) Emanuela Pupo et al. Frontiers in Oncology
- New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
- (2019) Haitang Yang et al. Frontiers in Oncology
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- A Comparative Analysis of Individual RAS Mutations in Cancer Biology
- (2019) Carmen Muñoz-Maldonado et al. Frontiers in Oncology
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
- (2019) Brian A. Lanman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Clonal Hematopoiesis: A new layer in the liquid biopsy story in lung cancer
- (2018) Joshua Bauml et al. CLINICAL CANCER RESEARCH
- Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer
- (2018) Shuai Li et al. CLINICAL CANCER RESEARCH
- False positive plasma genotyping due to clonal hematopoiesis
- (2018) Yuebi Hu et al. CLINICAL CANCER RESEARCH
- Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
- (2018) David R. Spigel et al. Journal of Thoracic Oncology
- Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients
- (2018) Alexander T. Falk et al. LUNG CANCER
- KRAS -Mutant Non-Small Cell Lung Cancer: From Biology to Therapy
- (2018) Irene Ferrer et al. LUNG CANCER
- KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
- (2018) Marta Román et al. Molecular Cancer
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Brief Report: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small-Cell Lung Cancer
- (2018) Jessica J. Lin et al. Journal of Thoracic Oncology
- Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC
- (2018) Massimo Moro et al. Journal of Thoracic Oncology
- Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
- (2018) Yosuke Miura et al. Cancers
- KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
- (2018) Sandra Misale et al. CLINICAL CANCER RESEARCH
- Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer
- (2018) Arnaud Jeanson et al. Expert Review of Anticancer Therapy
- Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate
- (2018) Jacek Kordiak et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy
- (2018) Caroline E. McCoach Journal of Thoracic Oncology
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
- (2017) Francesco Facchinetti et al. LUNG CANCER
- Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
- (2017) Rodrigo Romero et al. NATURE MEDICINE
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
- (2017) Emmet J. Jordan et al. Cancer Discovery
- Implications of KRAS mutations in acquired resistance to treatment in NSCLC
- (2017) Marzia Del Re et al. Oncotarget
- Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
- (2017) Jung Han Kim et al. Oncotarget
- Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery
- (2016) Stéphane Renaud et al. BRITISH JOURNAL OF CANCER
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer
- (2016) Ádám Nagy et al. INTERNATIONAL JOURNAL OF CANCER
- 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC
- (2016) D.L. Gibbons et al. Journal of Thoracic Oncology
- 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
- (2016) M.-J. Ahn et al. Journal of Thoracic Oncology
- The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma
- (2016) Anna Biernacka et al. Cancer Genetics
- Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
- (2016) Boram Lee et al. Oncotarget
- RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
- (2016) Hidetoshi Sumimoto et al. PLoS One
- RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
- (2015) J. Downward CLINICAL CANCER RESEARCH
- Meta-analysis of Epidermal Growth Factor Receptor and KRAS Gene Status between Primary and Corresponding Metastatic Tumours of Non-small Cell Lung Cancer
- (2015) S. Wang et al. CLINICAL ONCOLOGY
- Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer
- (2015) Wouter W. Mellema et al. LUNG CANCER
- Intra-tumoral Heterogeneity ofKRASandBRAFMutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
- (2015) Susan D. Richman et al. Analytical Cellular Pathology
- KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
- (2014) Ernest Nadal et al. Journal of Thoracic Oncology
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- The prognostic and predictive value ofKRASoncogene substitutions in lung adenocarcinoma
- (2013) Liza C. Villaruz et al. CANCER
- Pooled Analysis of the Prognostic and Predictive Effects ofKRASMutation Status andKRASMutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
- (2013) Frances A. Shepherd et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value
- (2013) Wouter W. Mellema et al. Journal of Thoracic Oncology
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- EGFR,KRAS,BRAF, andHER-2molecular status in brain metastases from 77 NSCLC patients
- (2013) Claire Villalva et al. Cancer Medicine
- Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer
- (2012) Winfried H. Alsdorf et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
- (2012) Julian R. Molina et al. MAYO CLINIC PROCEEDINGS
- Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer
- (2012) Linda Leung et al. Therapeutic Advances in Medical Oncology
- A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
- (2011) Gregory J. Riely et al. Journal of Thoracic Oncology
- Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls
- (2011) Aude Lamy et al. MODERN PATHOLOGY
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started